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Abstract
Background:  T u b e r c u l o s i s  ( T B )  i s  i n c r e a s i n g  i n  t h e world and drug-resistant (DR) disease
beckons new treatments.
Methods: To evaluate the action of interferon (IFN) gamma as immunoadjuvant to chemotherapy
on pulmonary DR-TB patients, a pilot, open label clinical trial was carried out in the Cuban
reference ward for the management of this disease. The eight subjects existing in the country at
the moment received, as in-patients, 1 × 106 IU of recombinant human IFN gamma intramuscularly,
daily for one month and then three times per week up to 6 months as adjuvant to the indicated
chemotherapy, according to their antibiograms and WHO guidelines. Sputum samples collection
for direct smear observation and culture as well as routine clinical and thorax radiography
assessments were done monthly.
Results: Sputum smears and cultures became negative for acid-fast-bacilli before three months of
treatment in all patients. Lesion size was reduced at the end of 6 months treatment; the lesions
disappeared in one case. Clinical improvement was also evident; body mass index increased in
general. Interferon gamma was well tolerated. Few adverse events were registered, mostly mild;
fever and arthralgias prevailed.
Conclusions: These data suggest that IFN gamma is useful and well tolerated as adjunctive therapy
in patients with DR-TB. Further controlled clinical trials are encouraged.
Background
Tuberculosis (TB) is not yet a defeated affection. Although
controllable at a community level and curable in individ-
uals, its eradication seems distant. At present, at least one
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third of the World's population, more than 1 500 million
individuals are infected with the Mycobacterium tuberculo-
sis. Every year, around 8 – 10 million new cases occur [1].
Two million people die annually due to non-AIDS related
TB, which is the highest number of deaths attributable to
a single infectious agent [2], and corresponds to the 7th
cause of death worldwide [3]. TB represents 26 % of
avoidable deaths in developing countries [4]. The emer-
gency of drug resistant (DR) or multidrug-resistant (MDR)
strains has increased this global problem, leading to a
high morbidity and mortality [5]. MDR-TB affected
patients' mean survival ranges from 2 to 14 months [6].
According to the World Health Organization's (WHO)
data, MDR patients global proportion is 2.2 % [7].
The infection is mainly transmitted by inhalation of the
bacilli coming from respiratory airways infected secre-
tions. Once inhaled, the bacilli are subjected to phagocy-
tosis within the alveolar macrophages, where they can be
destroyed. Nevertheless, Mycobacteria  have developed
mechanisms to adapt to the noxious intracellular environ-
ment. Thus, it can persist, replicate and disseminate, lead-
ing to new infectious foci. Resistance emergence depends
on several factors such as initial bacillary load, inadequate
or incomplete chemotherapy administration, and the
patient's immune condition.
Chemotherapy is successful in most cases, given that the
treatment schedule is thoroughly followed. It is pro-
longed, costly, and needs to be directly observed. Other-
wise it is inadequate to kill all the bacilli and drug
resistance emerges. Toxicities are frequent as well [8].
The immunologic approach to TB treatment can be prom-
ising since only 10 – 20% of infected people develop the
disease and many of them have spontaneous remission
[9]. Interferon (IFN) gamma plays a main role in the
immunity to TB. It is a glycoprotein, secreted by CD4+,
CD8+ and NK cells. Nevertheless, CD4+ Th1 lymphocytes
are the main producers in response to a stimulus [10].
Enough evidences exist related to IFN gamma action on
the macrophages immunoregulatory activity [11-14]].
Lack of production of this cytokine [15] or expression of
its receptor [16,17] is associated to the infection's most
lethal forms. Interferon gamma has also a potent antifi-
brotic effect [18-20].
Therefore a pilot clinical study was done with the aim to
evaluate IFN gamma effect on drug resistant pulmonary
TB patients regarding their clinical, bacteriological and
radiological evolutions. The results show that the use of
this protein in eight DR-TB patients (four of them MDR)
as adjuvant to antibiotics had short and middle-term ben-
eficial effects.
Methods
An open-label, non-randomized, non-controlled, pilot
trial was carried out at the "Benéfico -Jurídico" Hospital,
Havana, which is the national reference unit for TB and
other respiratory diseases. According to the national TB
program, all patients with unfavorable response to treat-
ment are remitted to this center.
The study population was constituted by eight Cuban
patients, both sexes, more than eighteen years old, with
diagnosis of TB without a favorable response to the usual
therapy, who gave their written, informed consent to par-
ticipate. The diagnosis comprised clinical findings such as
cough and expectoration, pulmonary lesions at thorax
radiography, and positive DR-TB sputum-smear and cul-
ture. To confirm drug resistance the Canetti's multiple
proportions method [21] was used as antibiogram. Exclu-
sion criteria were another chronic disease, pregnancy or
nursing, severe psychiatric dysfunction, multiple sclerosis
or another autoimmune disorder, other pulmonary infec-
tions, HIV co-infection, and treatment with glucocorti-
coids or any other immunosuppressor medication.
The previous drug therapy received by the patients
included 4 drugs (isoniazid, rifampin, streptomycin, and
pyrazinamide) daily during 2 months, then isoniazid and
rifampin twice per week for 2 additional months. Since
their sputum tests had not become negative at this point
they were returned to the 4 drugs regime plus ethambutol
daily for 3 months, and finally isoniazid, rifampin, and
ethambutol three times per week for 5 months.
The trial was done in compliance with the Helsinki Decla-
ration. The protocol was approved by the hospital's Ethics
Committee and by the Cuban Regulatory Authority. Data
from nineteen historical control cases were obtained from
the hospital's archives.
Patients received 1 000 000 IU of human recombinant
IFN gamma (Heberon Gamma R®, Heber Biotec, Havana),
intramuscularly, daily during 4 weeks and then 3 times
per week for the next 20 weeks. Participants stayed as in-
patients during the study period. They received anti-TB
drugs (WHO schemes) [22], according to the resistance
detected in each case by the antibiogram (Table 1). Drugs
were given as follows: rifampin 10 mg/Kg (maximum 600
mg), ethambutol 20 mg/Kg (max. 1500 mg), ethionamide
10 mg/Kg (max. 750 mg), pyrazinamide 15–30 mg/Kg
(max. 2000 mg), ciprofloxacin 15–20 mg/Kg (max. 1500
mg), amikacin 15 mg/Kg (max. 1000 mg), and kanamycin
15 mg/Kg (max. 1000 mg) daily. After the end of the 6-
months IFN gamma treatment period, chemotherapy con-
tinued up to 9 months if the scheme included rifampin
and 18 months otherwise.BMC Infectious Diseases 2004, 4:44 http://www.biomedcentral.com/1471-2334/4/44
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Evaluations were carried out at entry and monthly during
IFN gamma treatment. A complete physical examination
was done. Sputum samples were taken for acid-fast-bacilli
smear and culture, as well as blood samples for hemato-
logical counts, globular sedimentation rate, alanine ami-
notransferase, and creatinin determinations. Thorax
radiographies were also recorded. Afterwards, patients
were followed up with half-yearly evaluations during one
year.
Treatment efficacy evaluation included clinical, bacterio-
logical and radiological outcomes. Complete response
was defined as total disappearance of all signs and symp-
toms, negative sputum acid-fast-bacilli smear and culture,
and pulmonary lesions improvement at X-ray. Partial
response included signs and symptoms decrease, negative
sputum smear and culture and stable X-ray lesions. No
response consisted in signs and symptoms persistence,
positive bacteriological examinations, and lesions stabili-
zation or progression. Safety and tolerability of the IFN
gamma treatment were monitored by means of a rigorous
control of the adverse events that could be presented.
Results
Eight patients were enrolled in the study. Those were all
the pulmonary DR-TB cases in the country during the
inclusion period, from December 1999 to February 2002.
They had not responded to the usual Directly Observed
Treatment Short-course (DOTS) chemotherapy regime.
Strain resistance was acquired in all cases. This was well
determined since in Cuba all detected cases are screened
for resistance on their first isolate. The patients did not
have any extra-pulmonary manifestation of the disease.
Their demographic and baseline characteristics are shown
in Table 1. Five of them were men, six of them non-white.
The age ranged between 23 and 54 years old, and body
mass index (BMI) between 13.2 and 22.0 Kg/m2. Their
main symptoms were cough, expectorations, dyspnea,
stertors, distal cyanosis, and finger clubbing. Bacteriologi-
cal tests codification was mostly high and all patients
showed active lesions at thorax radiography. Most of them
had accelerated globular sedimentation rates (GSR). Ane-
mia or other hematological alterations were not recorded.
A rapid favorable evolution was obtained after treatment
with IFN gamma (Table 2). Clinical improvement was evi-
dent since the first month of treatment, when all signs and
symptoms (except for finger clubbing) had disappeared in
all patients and BMI increased in all but one of them. Spu-
tum acid-fast-bacilli smears and cultures were negative
since the 1 – 3 months of treatment. The eight patients
had radiological improvement, with lesions size reduc-
tion (total disappearance in one case) (Figure 1). GSR
decreased in five out of 6 patients who had abnormal val-
ues at inclusion. After six additional months follow-up,
patients # 3 and 4 normalized it to 10 and 15 mm/h,
respectively. At the end of the IFN gamma treatment all
the patients were evaluated as complete responders.
The treatment with IFN gamma was safe and well toler-
ated. Four patients presented at least one adverse event.
These events were arthralgias, fever, headache and asthe-
Table 1: Demographic and baseline characteristics of patients with DR-TB treated with IFN gamma
P a t i e n t 12345678
Age (years) 28 50 54 27 44 50 23 37
Sex Male Male Female Female Male Male Female Male
Race Mestizo White Mestizo Mestizo White Mestizo Black Black
BMI (Kg/m2) 19.6 18.9 13.2 18.3 14.6 21.6 22.0 17.1
Sputum smear status* 09998989
Sputum culture status** 79796989
Drug Resistance INH
RIF
STR
INH
STR
INH
RIF
STR
INH
RIF
INH, STR INH
RIF
STR
INH INH
Initial thorax X-ray R1 R2 R3 R4 R5 R6 R7 R8
GSR (mm/h) 5 66 53 53 68 101 10 60
INH: Isoniazid; RIF: Rifampin; STR: Streptomycin; ETB: Ethambutol; ETN: Ethionamide; PRZ: Pyrazinamide; CPF: Ciprofloxacin; KAN: Kanamycin; 
AMK: Amikacin.
* Number of bacilli; 0: 0 in 4 lines; 8: 25 or more in 1 line; 9: bacilli in most of the fields.
** Number of colonies; 6: 6–24 colonies; 7: 25–100 colonies; 9: confluent growth.
R1 and R3. Extensive bilateral exudative lesions
R2: Moderate exudative lesions
R4: Left fibro-exudative lesions
R5: Moderate Bilateral fibro-exudative lesions.
R6: Cavitary lesions at superior lobes; fibrous lesions at right superior lobe; alveolar infiltrate at left superior lobe.
R7 and R8: Very diffuse fibromatous lesions at superior lobes.BMC Infectious Diseases 2004, 4:44 http://www.biomedcentral.com/1471-2334/4/44
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nia. All adverse events were mild, except for one moderate
fever, which was efficiently controlled with acetami-
nophen. Significant differences were not detected in other
clinical laboratory tests.
After completion or the IFN gamma 6-months treatment
the patients continued with the corresponding chemo-
therapy schedule. Seven of the eight patients remained
bacteriologically, clinically and radiologically negative at
least twelve months after the treatment with IFN gamma
concluded. However, patient number five relapsed six
months after the end of IFN therapy. He developed addi-
tional resistance to rifampin and ethionamide and a
chronic obstructive respiratory disease that contributed
negatively to his evolution.
Table 3 shows the results obtained at the same hospital
with the 19 DR-TB cases during the five years prior to the
present study. These patients had also failed to the stand-
ard DOTS regime. They were all resistant to isoniazid and
rifampin, 13 were resistant to streptomycin, 7 to kanamy-
cin, 4 to ethambutol, and one to pyrazinamide. Resistance
was primary in 2 cases and acquired in the rest. Their aver-
age age was 58 years. Management was essentially the
same as for the patients included in the study, except for
IFN gamma treatment. None of these DR-TB cases reached
culture conversion at three months of treatment with
chemotherapy and less than half had converted at six
months. Their clinical outcome was also worse.
Discussion
In spite of the reduced size of the population studied, the
results suggest the efficacy of IFN gamma on DR-TB, when
used as adjuvant to chemotherapy. All eight patients were
considered as complete responders at the end of IFN
treatment with disappearance of the disease signs and
symptoms, sputum tests conversion, and pulmonary
lesions improvement. Bacteriological and radiological
improvement correlated with the clinical evolution; BMI
increased and manifestations as cough and expectoration
did not recur after IFN gamma treatment. Clinical practice
demonstrates that these results are very difficult to obtain
in such a short period of time with the chemotherapy
alone.
Any conclusion from this study is also limited by the fact
that it was not a controlled trial. This was not possible due
to the low incidence of TB (7.6/100,000 inhabitants in
2002) [23] and DR-TB in Cuba [7]. Therefore a historical
control with the results obtained at the same hospital by
the same investigators in patients treated only with chem-
otherapy is used for comparison. Despite the fact that this
kind of control is not fully comparable since they were not
in the original design of the trial, a clear difference is
shown regarding patients' performance. Literature reports
on chemotherapy-treated DR-TB patients show similar
unfavorable outcome [6].
The fact that four patients received rifampin, according to
the strain sensitivity, which is one of the election drugs for
the treatment of TB with excellent results in patients
treated with DOTS regime, does not diminish the consid-
Table 2: Six months follow-up data of DR-TB patients treated with IFN gamma
P a t i e n t 1 2 345678
Drug regimen ETB ETB ETB ETB
RIF RIF RIF RIF
ETN ETN ETN ETN
ETB ETB ETB ETB
PRZ PRZ PRZ PRZ
PRZ PRZ PRZ PRZ
CPF CPF CPF CPF
KAN KAN KAN KAN
KAN KAN AMK KAN
Gain BMI (Kg/m2) 1.8 0.4 0.4 0.4 0.3 2.2 1.8 - 2.1!
Sputum smear status Negative Negative Negative Negative Negative Negative Negative Negative
Sputum culture status Negative Negative Negative Negative Negative Negative Negative Negative
Conversion time 2 mo. 3 mo. 3 mo. 1 mo. 3 mo. 2 mo. 2 mo. 3 mo.
Thorax X-ray Residual 
fibrosis
Reabsorption 
and residual 
fibrosis
Residual 
bilateral 
fibrosis.
Lesions 
resolution
Residual 
fibrosis
Lesions size 
reduction
Residual 
fibrosis
Lesions size 
reduction
GSR (mm/h) 5 4 8 2 64 04 22 02 37 7
Legend: see Table 1
! Lost body weightBMC Infectious Diseases 2004, 4:44 http://www.biomedcentral.com/1471-2334/4/44
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eration regarding the possible benefit exerted by IFN
gamma since these same patients had already not
responded to this antibiotic as part of the DOTS. Moreo-
ver, one patient recurred after he had finished IFN gamma
treatment for 6 months, despite still being under chemo-
therapy regime. This suggests that in his case a new IFN
gamma cycle combined to the antibiotics would have
been necessary, but this was not previewed in the proto-
col. However, only a controlled trial can definitely clarify
the role of IFN gamma and second line antibiotics in this
kind of patient's improvement.
Radiological improvement with IFN gamma treatment (ray-x of two patients are shown) Figure 1
Radiological improvement with IFN gamma treatment (ray-x of two patients are shown). Patient 4 (A), left-lung fibroexudative 
lesions, and (B) complete resolution after IFN gamma treatment. Patient 2 (C), bilateral moderate exudative lesions before IFN 
gamma treatment, and (D) important improvement of the lesions afterwards.
B A
D CBMC Infectious Diseases 2004, 4:44 http://www.biomedcentral.com/1471-2334/4/44
Page 6 of 8
(page number not for citation purposes)
The radiological results demonstrated IFN gamma antifi-
brotic properties as well. All patients had a reduction in
the pulmonary lesions size, while one showed a complete
resolution. This effect cannot be attributable to the antibi-
otics, since it is well known that DR-TB patients only
develop radiological improvement long time after spu-
tum smears and culture become negative. In many cases
extensive fibrotic lesions never improve, and stay stable
for life. This antifibrotic action agrees with that obtained
with IFN gamma in idiopathic lung fibrosis [24] and sug-
gests that IFN gamma can have future indications in other
pulmonary diseases where fibrosis is present.
Therapy was well tolerated. It was not necessary to sus-
pend the combined treatment due to adverse events;
mostly mild. Adverse events such as arthralgias, fever and
headache coincide with those reported for interferons
[25].
Immunity to TB depends on the development of CD4+
cells- and macrophages-mediated Th1 response. The role
of IFN gamma as the main macrophage-activator Th1
cytokine has been clearly established in animal models
infected with M. tuberculosis [15,26,27]. IFN gamma
action on the macrophages leads to kill intracellular Myco-
bacteria. It stimulates macrophages to produce tumor
necrosis factor alpha (TNF α), oxygen free radicals and
nitric oxide, increase surface display of MHC antigens and
Fc receptors, decrease lysosomal pH, and increase the
intracellular concentration of some antibiotics [11-
14,28].
Regarding its antifibrotic effect, IFN gamma inhibits lung
fibroblast proliferation and chemotaxis in a dose depend-
ent manner, and reduces collagen synthesis [18,19,29].
Furthermore, this protein is a potent inhibitor of the
transforming growth factor β (TGF-β)[20], involved in the
pathogenesis of many fibrotic lung diseases [30-32].
On the other hand, mutations in the IFN gamma gene
[15], or in the IFN gamma receptor alpha chain gene
[16,17], increase susceptibility to develop the disease.
Patients with disseminated BCG and other infections
present defects in IFN gamma and other cytokines secre-
tion and action [33-35].
IFN gamma therapy has been shown effective for cerebral
tuberculosis caused by a multidrug-resistant strain [36].
The aerosol route of administration has been proposed as
organ specific delivery method, obtaining a high release to
infected alveoli [37]. Condos et al. reported clinical and
bacteriological improvement and tolerability with aero-
solized IFN gamma in five patients with MDR-TB [38]. In
addition, other previous trials demonstrated promising
results in patients infected with other Mycobacteria [10,39-
42].
Conclusions
These results can suggest a beneficial effect of IFN gamma
when it is used as adjuvant in the treatment of tuberculo-
sis patients that have resistance to standard chemother-
apy, and encourage carrying out more extensive,
controlled studies. Combination with second-line drugs
can reduce the time of treatment, diminishing toxicities
and possible relapses; in many cases could reduce the
application of recessional surgery. Further controlled clin-
ical trials are needed to confirm these results.
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